CUA Events

Home

Home

Monitoring Prostate Cancer to Guide Treatment Decision-Making

Accreditation Statement

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.

Instructions

Step 1 - Complete the survey below.
Step 2 - Take the Pre-Test
Step 3 - Watch the Video
Step 4 - Take the Post-Test
Step 5 - Complete the evaluation at the end to receive your Section 3 certificate of participation

Please rate how often you agree with the following statements:

1. In my practice, I feel comfortable deciding which patients with newly diagnosed mCSPC should be offered docetaxel, abiraterone, or ADT alone.

(*)

Always
Almost Always
Sometimes
Never Invalid Input

2. I can anticipate and recognize the possible/probable toxicities of the following therapies and I am comfortable with the necessary toxicity monitoring:

a. Abiraterone / prednisone(*)

Always
Almost Always
Sometimes
Never Invalid Input

b. Enzalutamide, apalutamide(*)

Always
Almost Always
Sometimes
Never Invalid Input

c. Docetaxel(*)

Always
Almost Always
Sometimes
Never Invalid Input

3. I routinely refer my patients with advanced prostate cancer in the following clinical scenario to a medical oncologist for an opinion and multidisciplinary care:

a. mCSPC(*)

Always
Almost Always
Sometimes
Never Invalid Input

b. m0 CRPC(*)

Always
Almost Always
Sometimes
Never Invalid Input

c. m1CRPC, ARAT (abiraterone or enzalutamide naïve)(*)

Always
Almost Always
Sometimes
Never Invalid Input

d. m1 CRPC, progressing on ARAT(*)

Always
Almost Always
Sometimes
Never Invalid Input